221 related articles for article (PubMed ID: 31370301)
1. Nanobodies that Neutralize HIV.
Weiss RA; Verrips CT
Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31370301
[TBL] [Abstract][Full Text] [Related]
2. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
Front Immunol; 2022; 13():893648. PubMed ID: 35651621
[TBL] [Abstract][Full Text] [Related]
3. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
4. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
5. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
[TBL] [Abstract][Full Text] [Related]
6. Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes.
Strokappe NM; Hock M; Rutten L; Mccoy LE; Back JW; Caillat C; Haffke M; Weiss RA; Weissenhorn W; Verrips T
Antibodies (Basel); 2019 Jun; 8(2):. PubMed ID: 31544844
[TBL] [Abstract][Full Text] [Related]
7. A Two-Step Approach for the Design and Generation of Nanobodies.
Wagner HJ; Wehrle S; Weiss E; Cavallari M; Weber W
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400198
[TBL] [Abstract][Full Text] [Related]
8. Applications of nanobodies in plant science and biotechnology.
Wang W; Yuan J; Jiang C
Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
[TBL] [Abstract][Full Text] [Related]
9. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
10. Development of Antibody and Nanobody Tools for P2X7.
Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.
Jähnichen S; Blanchetot C; Maussang D; Gonzalez-Pajuelo M; Chow KY; Bosch L; De Vrieze S; Serruys B; Ulrichts H; Vandevelde W; Saunders M; De Haard HJ; Schols D; Leurs R; Vanlandschoot P; Verrips T; Smit MJ
Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20565-70. PubMed ID: 21059953
[TBL] [Abstract][Full Text] [Related]
12. Nanobodies®: new ammunition to battle viruses.
Vanlandschoot P; Stortelers C; Beirnaert E; Ibañez LI; Schepens B; Depla E; Saelens X
Antiviral Res; 2011 Dec; 92(3):389-407. PubMed ID: 21939690
[TBL] [Abstract][Full Text] [Related]
13. Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Easterhoff D; Bradley T; Luo K; Williams WB; Liao HX; Moody MA; Phad GE; Vázquez Bernat N; Melillo B; Santra S; Smith AB; Karlsson Hedestam GB; Haynes B; Sodroski J
J Virol; 2016 May; 90(10):5031-5046. PubMed ID: 26962221
[TBL] [Abstract][Full Text] [Related]
14. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
[TBL] [Abstract][Full Text] [Related]
15. Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V; Zarca AM; Van Hout A; Arimont M; Doijen J; Bialkowska M; Toffoli E; Klarenbeek A; van der Woning B; van der Vliet HJ; Van Loy T; de Haard H; Schols D; Heukers R; Smit MJ
Biochem Pharmacol; 2018 Dec; 158():413-424. PubMed ID: 30342023
[TBL] [Abstract][Full Text] [Related]
16. Construction of an alpaca immune antibody library for the selection of nanobodies against
Qiu J; Li J; Zhang Z; Dong S; Ling X; Fang Z; Ling Q; Huang Z
Front Bioeng Biotechnol; 2023; 11():1207048. PubMed ID: 37362207
[No Abstract] [Full Text] [Related]
17. Discrete analysis of camelid variable domains: sequences, structures, and in-silico structure prediction.
Melarkode Vattekatte A; Shinada NK; Narwani TJ; Noël F; Bertrand O; Meyniel JP; Malpertuy A; Gelly JC; Cadet F; de Brevern AG
PeerJ; 2020; 8():e8408. PubMed ID: 32185102
[TBL] [Abstract][Full Text] [Related]
18. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
19. Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41.
Matsuda S; Noda M
Microbiol Immunol; 2000; 44(11):923-9. PubMed ID: 11145273
[TBL] [Abstract][Full Text] [Related]
20. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes.
Llorente M; Sánchez-Palomino S; Mañes S; Lucas P; Kremer L; De Alborán IM; Torán JL; Alcamí J; Del Real G; Martínez-A C
Scand J Immunol; 1999 Sep; 50(3):270-9. PubMed ID: 10447936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
